(R)-吡咯烷-3-甲酰胺盐酸盐 | 1273577-42-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-吡咯烷-3-甲酰胺盐酸盐
• 英文名称: (R)-pyrrolidine-3-carboxamide hydrochloride
• 英文别名: (R)-pyrrolidine-3-carboxylic acid amide hydrochloride；(3R)-pyrrolidine-3-carboxamide;hydrochloride
• CAS: 1273577-42-6
• 化学式: C₅H₁₀N₂O*ClH
• 分子量: 150.608
• InChiKey: GCPFRHSIYOIWDY-PGMHMLKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  55.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-2-yl amine 、 (R)-吡咯烷-3-甲酰胺盐酸盐 在 三乙胺 作用下， 以 正丁醇 为溶剂， 反应 72.0h， 生成 (R)-1-(2-amino-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl)-pyrrolidine-3-carboxamide
  参考文献：
  名称：

  [EN] PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS DANS LE TRAITEMENT DU CANCER

  摘要：

  具有公式I或II的化合物，其中R1、X1和X2具有权利要求1中所示的含义，是MTH1抑制剂，可以用于治疗癌症。

  公开号：

  WO2016128140A1

文献信息

• [EN] SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES<br/>[FR] DIHYDROPYRAZOLO[4,3-B]INDOLES SUBSTITUÉES DANS LES POSITIONS 1 ET 4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014039831A1

  公开（公告）日：2014-03-13

  Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

  本公开涉及式（1）的化合物及其药用盐，其中L、R1、R2、R3、R4、R5、R6和R7在规范中定义。本公开还涉及制备式1化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗与MetAP2相关的肥胖和相关疾病、紊乱和病况的用途。
• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS
  申请人：COURTNEY STEPHEN MARTIN

  公开号：WO2013033068A1

  公开（公告）日：2013-03-07

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用可接受载体的药物组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用。还提供了筛选能够抑制KMO活性的化合物的方法。
• Cyclic amines
  申请人：Zbinden Groebke Katrin

  公开号：US20060247238A1

  公开（公告）日：2006-11-02

  The invention is concerned with cyclic amines of formula (I) wherein X 1 to X 3 , Y 1 to Y 3 , R 1′ , R 1″ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments and for treating diseases associated with coagulation factor Xa.

  这项发明涉及公式(I)中的环氨基化合物，其中X1至X3，Y1至Y3，R1'，R1"和n如描述和索赔中定义的那样，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa，并可用作药物治疗与凝血因子Xa相关的疾病。
• [EN] PYRROLOPYRIMIDINECARBOXAMIDES<br/>[FR] PYRROLOPYRIMIDINE CARBOXAMIDES
  申请人：NYCOMED GMBH

  公开号：WO2009106531A1

  公开（公告）日：2009-09-03

  The compounds of Formula (I) wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

  Formula（I）中的化合物，其中R1、R21、R22、R23、R24、Y和R3的含义如描述中所述，其盐，化合物的N-氧化物及其盐，化合物的立体异构体，盐，化合物的N-氧化物及其盐的N-氧化物是有效的第5型磷酸二酯酶抑制剂。
• FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS
  申请人：Laing Victoria Elizabeth

  公开号：US20090264411A1

  公开（公告）日：2009-10-22

  A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

  一系列4,5,6,7-四氢噻吩[2,3-c]唑啉-8-酮衍生物及其类似物，在2位被取代的苯胺基团取代下，是选择性抑制人类MEK（MAPKK）酶的，因此在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增生（包括肿瘤）和疼痛性疾病方面。